Corcept Q2 revenue up 39% to $163.8M; raises 2024 guidance to $640-670M

CORCEPT THERAPEUTICS INC

2024-Q2 EPS reported $0.57 revenue$310,604,000

Q2 revenue $163.8M, up 39% YoY; diluted EPS $0.32 vs $0.25.
2024 revenue guidance raised to $640-670M from $620-650M.
Cash and investments $492.5M at June 30, up from $451M at March 31.
NDA submission for relacorilant in Cushing's syndrome expected Q4; late-stage trial results (ROSELLA, GRADIENT, DAZALS) due by year-end.
Record number of new Korlym prescribers and patients; hypercortisolism screening expanding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.